Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human

References

• Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. 2011. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 13:e17. doi:10.1017/S1462399411001888.
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, et al. 2014. Mutational profiling of kinases in glioblastoma. BMC Cancer. 14(1):718. doi:10.1186/1471-2407-14-718.
   PubMedGoogle Scholar
• Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. 2013. The somatic genomic landscape of glioblastoma. Cell. 155(2):462–477. doi:10.1016/j.cell.2013.09.034.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095. doi:10.1023/a:1018943613122.
   PubMed Web of Science ®Google Scholar
• de Gooijer MC, Kemper EM, Buil LCM, Çitirikkaya CH, Buckle T, Beijnen JH, van Tellingen O. 2021. ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Rep Med. 2(1):100184. doi:10.1016/j.xcrm.2020.100184.
   PubMedGoogle Scholar
• Ellingson BM, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, et al. 2020. Multiparametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in patients with recurrent high-grade glioma. Clin Cancer Res. 26(13):3135–3144. doi:10.1158/1078-0432.CCR-19-3817.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al. 2009. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27(28):4733–4740. doi:10.1200/JCO.2008.19.8721.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker.
   Google Scholar
• Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD, et al. 2016. Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR. ACS Med Chem Lett. 7(4):351–356. doi:10.1021/acsmedchemlett.6b00005.
   PubMed Web of Science ®Google Scholar
• Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, et al. 2017. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol. 19(1):128–137. doi:10.1093/neuonc/now135.
   PubMed Web of Science ®Google Scholar
• Huang L, Wells MC, Zhao Z. 2019. A practical perspective on the evaluation of small molecule CNS penetration in drug discovery. Drug Metab Lett. 13(2):78–94. doi:10.2174/1872312813666190311125652.
   PubMedGoogle Scholar
• Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, Anderson BD, Unadkat JD. 2007. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos. 35(9):1459–1462. doi:10.1124/dmd.107.016220.
   PubMed Web of Science ®Google Scholar
• Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. 2011. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther. 339(3):935–944. doi:10.1124/jpet.111.180398.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al. 2009. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 27(5):740–745. doi:10.1200/JCO.2008.16.3055.
   PubMed Web of Science ®Google Scholar
• Lin JH. 2008. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. 9(1):46–59. doi:10.2174/138920008783331077.
   PubMed Web of Science ®Google Scholar
• Liu EK, Sulman EP, Wen PY, Kurz SC. 2020. Novel therapies for glioblastoma. Curr Neurol Neurosci Rep. 20(7):19. doi:10.1007/s11910-020-01042-6.
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Vora B, Zhu R, Apt D, Olivero AG, Ware JA, Mueller LU, Cloughesy T, Gerstner E, Rodon J, et al. 2016. Clinical pharmacokinetics and brain penetration of GDC-0084, an oral PI3K/mTor inhibitor in patients with high-grade glioma. Clin Pharmacol Ther. 99:S5–S107.
   Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 283(1):46–58.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. 2022. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 24(Suppl 5):v1–v95. doi:10.1093/neuonc/noac202.
   PubMedGoogle Scholar
• Pardridge WM. 2011. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers Cns. 8(1):7. doi:10.1186/2045-8118-8-7.
   PubMedGoogle Scholar
• Patel NC, Feng B, Hou X, West MA, Trapa PE, Sciabola S, Verhoest P, Liras JL, Maurer TS, Wager TT. 2021. Harnessing Preclinical data as a predictive tool for human brain tissue targeting. ACS Chem Neurosci. 12(6):1007–1017. doi:10.1021/acschemneuro.0c00807.
   PubMed Web of Science ®Google Scholar
• Salphati L, Alicke B, Heffron TP, Shahidi-Latham S, Nishimura M, Cao T, Carano RA, Cheong J, Greve J, Koeppen H, et al. 2016. Brain distribution and efficacy of the brain penetrant PI3K Inhibitor GDC-0084 in orthotopic mouse models of human glioblastoma. Drug Metab Dispos. 44(12):1881–1889. doi:10.1124/dmd.116.071423.
   PubMed Web of Science ®Google Scholar
• Salphati L, Lee LB, Pang J, Plise EG, Zhang X. 2010. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 38(9):1422–1426. doi:10.1124/dmd.110.034256.
   PubMed Web of Science ®Google Scholar
• Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X. 2012. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos. 40(9):1785–1796. doi:10.1124/dmd.112.046052.
   PubMed Web of Science ®Google Scholar
• Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D, Wallin JJ. 2010. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 38(9):1436–1442. doi:10.1124/dmd.110.032912.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, et al. 2018. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20(2):184–191. doi:10.1093/neuonc/nox175.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352(10):987–996. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, et al. 2020. First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR Inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin Cancer Res. 26(8):1820–1828. doi:10.1158/1078-0432.CCR-19-2808.
   PubMed Web of Science ®Google Scholar
• Wen PY, de Groot JF, Battiste J, Goldlust SA, Garner JS, Friend J, Simpson JA, Damek D, Olivero AG, Cloughesy TF. 2022. Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: final phase 2 study results. J Clin Oncol. 40(16_suppl):2047–2047. doi:10.1200/JCO.2022.40.16_suppl.2047.
   Web of Science ®Google Scholar
• Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, Hop CE, et al. 2012. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res. 18(14):3846–3855. doi:10.1158/1078-0432.CCR-12-0738.
   PubMed Web of Science ®Google Scholar
• Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, et al. 2012. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 18(11):3090–3099. doi:10.1158/1078-0432.CCR-12-0445.
   PubMed Web of Science ®Google Scholar
• Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, Rohde E, Gan LS. 2012. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos. 40(4):779–787. doi:10.1124/dmd.111.043703.
   PubMed Web of Science ®Google Scholar